In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
about
A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyA modular IgG-scFv bispecific antibody topology.Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.Image guided biodistribution and pharmacokinetic studies of theranostics.Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.Prostate-specific membrane antigen-based therapeutics.86Y based PET radiopharmaceuticals: radiochemistry and biological applicationsAn engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.PET/CT Imaging and Radioimmunotherapy of Prostate CancerImproving external beam radiotherapy by combination with internal irradiationTargeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancerImmuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imagingSynthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancerH(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)LuA practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyAntibody vectors for imaging.Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.Matching chelators to radiometals for radiopharmaceuticals.Multifunctional radiolabeled nanoparticles: strategies and novel classification of radiopharmaceuticals for cancer treatment.Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragmentA comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.H4octapa: synthesis, solution equilibria and complexes with useful radiopharmaceutical metal ions.Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
P2860
Q30420026-5C22AE46-BDE1-45DF-8A92-5569F6B57963Q33519465-FB03BDB4-16AA-423C-B547-C1DA2A2B9910Q33661948-BE8A2AFD-1318-4EDC-9083-577863DF71D7Q33851546-3D753D04-34DC-4C2B-AF59-CD2E0F01E816Q34313174-CE93CB69-1E91-4AC7-86D1-7D7357FB0475Q34506838-10F192A8-D706-4A27-9D25-3C6A62F2FFBFQ35002038-0201404A-FBE0-48FC-B915-9231F5F57285Q35132944-CD472E1A-F413-4C16-B7FA-1B3041F806B1Q35250409-7FC8A38D-B123-43E6-8BE8-7B1361134D52Q35583305-8922F80D-3872-4609-B9CD-FD5EE294A9E0Q36085426-7440F5F5-717E-4732-A1F7-57B7037088F8Q36235732-A716E417-D660-4E59-8DCF-450008A8236DQ36745487-402C3C67-A22D-4346-8AD1-4465F01EB973Q36944360-E9E9FACB-0BAC-4A94-B193-EF4E5F8E688DQ37136748-5332A975-3022-4B21-A24B-4F2CF0F1A2BDQ37142624-EC92CE59-B6B1-446D-8A4A-41F5820413B3Q37172093-1CFBC84B-5B73-41D5-AB1E-AD0C46AB4482Q37689802-243C4BFA-D5F2-4C80-A303-C5E5FE0B1424Q37720850-ED8DE165-006A-4DEB-A422-336D2B37766AQ37864161-0981FB76-BB7F-462E-AFB4-5DD31A42E5D7Q37869905-B0EDAFC1-12F4-4BB1-B7EF-47E38A644793Q38156660-1AE3758E-286E-4DEB-BBA6-B416BF15FC83Q38297915-83E61671-8C48-4467-800A-D8AC67769A1CQ38860216-904E4CE2-0E2F-4B79-A331-08925306CA53Q39417962-B5E0DBCA-B940-4F3C-8B85-C83A4E690CE1Q41485304-E85BF997-4B92-4B38-A721-4BDC0F03F532Q46314544-3C262B52-C2E6-49B8-BCB3-6C98E2E46DC8Q47105948-6DA3D252-A6D4-43C5-A7C8-872A28AE2D90Q47735319-27D12F2E-3C17-4878-B39A-199353361205Q50026698-9193867D-B045-4D57-BEEC-F7CCFE0CC178Q57116004-AA62E4E3-86E0-44B0-BA19-E71C38EADA19
P2860
In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@en
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@nl
type
label
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@en
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@nl
prefLabel
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@en
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice.
@nl
P2093
P2860
P1476
In vivo biodistribution, PET i ...... LNCaP tumor-bearing nude mice
@en
P2093
Bruno Alicke
David R Light
Douglas W Schneider
Gordon Parry
Jeongsoo Yoo
Kirk McLean
Noboru Satozawa
Renate Parry
Tara Heitner
P2860
P304
P356
10.2967/JNUMED.108.055608
P407
P577
2009-02-17T00:00:00Z